ISPE Europe Annual Conference Announces Speaker Line-Up

Inaugural Event to Focus on Pharmaceutical Operations within the New Quality Culture

(PresseBox) ( Brussels, Belgium, )
Renowned pharmaceutical, regulatory and technology experts from around the world will speak at the very first ISPE Europe Annual Conference-Driving Effectiveness in Pharmaceutical Operations within the New Quality Culture scheduled for April 28 - 30 2014 in Frankfurt, Germany.

The programme will include an executive forum, keynote sessions and three different tracks to determine how operational challenges, quality system effectiveness and regulatory changes can merge with a new pharmaceutical paradigm.

The paramount speaker line-up includes over 60 top regulators; production, quality and development professionals. Prof.Dr Wolfram Carius, Senior Vice President, Biopharma; Joe DeFeo, President and CEO, Juran Institute, Inc.; John Pinion, Global Head of PT Quality and Compliance, Roche; Dr. Fergus Sweeney, Head of Inspections and Human Medicines Pharmacovigilance Division, European Medicines Agency; Dr. Martin Bergen, Managing Director, SecurPharm; Dr. Paul Rutten, Principal at McKinsey & Co; and Dr. Birgitte Holst, Director, Novo Nordisk/EFPIA, among many others, will deliver presentations addressing the industry's most pressing issues.

"This Annual Conference will provide a synoptic view to the challenges pharmaceutical operations are facing, from supply chain control, to the impact of new regulations on manufacturing and how to avoid drug shortages by installing a robust pharmaceutical quality system. Industry professionals will have the opportunity to discuss key issues with colleagues and with regulators from EFPIA, EMA, FDA along with national regulators of European countries" said the Executive Forum Chair Thomas Zimmer, Vice President, ISPE European Operations."

Speakers from companies such as Pfizer, Novartis, Juran Institute Inc., Sanofi - Aventis, Roche and others, will illustrate the new quality culture and clarify their visions for future operations. Sessions include topics such as the future of biopharmaceutical operations, the current drug shortages initiatives, the perceived trade-off between fulfilling GMP compliance and lean production, the implementation of the Falsified Medicines Directive and the future regulatory challenges.

For more information on this conference, including detailed agendas and registration information, visit:
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to